avct share chat

Avct share chat

We could not find any results for: Make sure your spelling is correct avct share chat try broadening your search. It looks like you aren't logged in. Click the button below to log in and view your recent history. Already a member?

They updated the market this morning that their technology maybe a potential therapy for blocking Covid Would like to see Avacta added. If you look up Myles McNulty on Twitter, the guy is an absolute guru when it comes to this company. Long story short, if their test results get validated in a clinical setting should find out about that in the next weeks then its going to go through the roof. Still a great entry point.

Avct share chat

Hey yeah finally could see numbers in green Thanks to you and Goldshare This is beginning to look suspiciously like a pump and dump to me. Lots of hype on Twitter pushing the price up, then it crashes, then repeats. Only inaccuracy is the talk of phase 3, which Ceo has stated unlikely to be required as its using a well known and understood drug. Imo phase 1a was the riskiest part, knowing that dox successfully cleaved and is present at much higher concentrations than in the blood stream. Final DE will be to see if there is a max tolerable dose before it becomes toxic, but Alastair Smith thinks it might not be found. What a load of bull … Or should I say bear. Cohort 6 ended. A terminal patient with STS is showing a reduction in tumour volume. This is a patient who has tried all standard dosing regimes of chemo and radiotherapy, and selflessly volunteered for a trial knowing its sole purpose was to see if the platform was safe for the benefit of others in years to come- it being something that would extend their life wasnt even considered a viable outcome. Even better is that phase 2 is being fast tracked to next year in the US and phase 1b is instead replaced with a short trial to decide if two weeks or three weeks dosing is better. Only disappointing thing is the lack of support pharma gets in the UK. I cannot believe the lack of conversation on Freetrade regarding Avacta. Wakey wakey DYOR.

We could not find any results for: Make sure your spelling is correct or try broadening your search, avct share chat. We could not find any results for: Make sure your spelling is correct or try broadening your search.

We could not find any results for: Make sure your spelling is correct or try broadening your search. It looks like you aren't logged in. Click the button below to log in and view your recent history. Already a member? Sign in. More Brokers. It looks like you are not logged in.

GBX Key events shows relevant news articles on days with large price movements. Greatland Gold plc. GGP 3. Argo Blockchain PLC. ARB 3. Eurasia Mining plc.

Avct share chat

We could not find any results for: Make sure your spelling is correct or try broadening your search. It looks like you aren't logged in. Click the button below to log in and view your recent history. Already a member?

Plan loft design

Got in late with this stock at 1. Recently viewed investments. More Brokers. This means our website may not look and work as you would expect. Trending Now. Big-g 1 November Your new shares will be credited to your account on Tuesday 19 March. It's the same old jam tomorrow stuff. Goldshare Sid 20 April Simmo Marc 6 October

.

Recently viewed shares. Year low : Al wants to turn us in to the next Roche, if he can fight off hostile bids over next decade he just might do it. Click the button below to log in and view your recent history. If you wish to submit an order outside of the product you currently hold your shares, please leave a note in the comments section of the application. Snapchat , watch out!! Open : Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more. Expecting mega price action on Monday and huge announcements from the prime minister down. And I forgot to mention the Brokers and other professionals.

1 thoughts on “Avct share chat

Leave a Reply

Your email address will not be published. Required fields are marked *